- NCBI Gene Id:
- Protein Name:
- T-cell surface glycoprotein CD4
- Alias Symbols:
- L3T4, Ly-4, Cd4
- Replacement Item:
- This antibody may replace item sc-1140 from Santa Cruz Biotechnology.
- Description of Target:
- RAT ANTI MOUSE CD4
- Protein Size (# AA):
- IHC-AFF, FC
- Tissue Tool:
- Find tissues and cell lines supported by DNA array analysis to express Cd4.
- RNA Seq:
- Find tissues and cell lines supported by RNA-seq analysis to express Cd4.
- Predicted Species Reactivity:
- Predicted Homology Based on Immunogen Sequence:
- Product Format:
- Purified IgG - liquid
- Reconstitution and Storage:
- Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- Printable datasheet for anti-Cd4 antibody - OASA05211
- Application Info:
- Flow Cytometry: 1/50 - 1/200
- Application Data:
- Application #1: Staining of mouse peripheral blood lymphocytes with Rat anti Mouse CD4: Alexa Fluor 405
Application #2: Staining of mouse peripheral blood lymphocytes with Rat anti Mouse CD4:FITC
Application #3: Staining of mouse spleen cells with Rat anti Mouse CD4: APC
Application #4: Staining of mouse spleen cells with Rat anti Mouse CD4
Application #5: Staining of mouse spleen cells with Rat anti Mouse CD4:RPE
- Preparation: Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preservative Stabilisers: 0.09% - Sodium Azide
- Approx Protein Conc: IgG concentration 1 mg/ml
Buffer Solutions: Phosphate buffered saline pH7.4
- Protocol Information:
- Citation: 1: Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A,Perry VH, Butters TD, Dwek RA, Platt FM. Central nervous system inflammation is ahallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain.2003 Apr;126(Pt 4):974-87. PubMed PMID: 12615653.
Experiment Name: Immunohistochemistry
Experiment Background: To survey for infammatory cells throughout the CNS, Tay-Sachs, LOTS, Sandhoff and GM1 gangliosidosis mouse models were analysed for infammatory markers (by list above in product section) by immunocytochemistry.
Experimental Steps: The staining method was based on the avidin-biotin peroxidase complex (ABC) technique of Hsu and colleagues (Hsu et al., 1981). Basic staining procedures for antibodies and lectins were adapted from Perry et al. (1985) and Mannoji et al. (1986), respectively. For age-dependent analysis of neuro-infammation, all age-point sections were processed simultaneously. The sections were incubated in a humid chamber at room temperature for 1-2 h with one of the following primary antibodies (listed above in product section).The primary antibodies were detected using one of the following species-specifc secondary antibodies: biotinylated rabbit anti-rat immunoglobulin G (IgG; Vector Laboratories, Peterborough, UK), biotinylated mouse anti-rabbit IgG (Sigma), biotinylated rabbit anti-goat (Vector Laboratories), biotinylated horse anti-mouse IgG, and Fluorescein or Texas Red horse anti-mouse (Vector Laboratories). The secondary(biotinylated) antibodies were detected using ABC kit (Vectastain) and developed with 3.3’-diaminobenzidine (DAB). In control incubation, the primary antibody was replaced by an appropriate non-immune IgG to verify the specifcity of staining.
Other Reagents Used: Paraformaldehyde, sucrose
Number Of Protocols: 1
- Target Reference:
- 1. Cobbold, S.P. et al. (1990) The induction of skin graft tolerance in MHC-mismatched or primed recipients: primed T cells can be tolerized in the periphery with CD4 and CD8 antibodies. Eur. J. Immunol. 20: 2747-2755.
2. Bemelman, F. et al. (1998) Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. J. Immunol. 160: 2645-2648.
3. Higgins, L. M. et al. (1999) Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 Ligand Interaction: Amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand - IgG fusion protein. J. Immunol. 162: 486 - 493.